Szymczyk Agnieszka, Macheta Arkadiusz, Podhorecka Monika
Independent Clinical Transplantology Unit, Medical University of Lublin, Lublin, Poland,
Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.
Cancer Manag Res. 2018 Oct 8;10:4267-4277. doi: 10.2147/CMAR.S174476. eCollection 2018.
Research on the carcinogenesis process is currently focused primarily on understanding its genetic basis and molecular abnormalities that may be predictive factors and therapeutic targets. It was clearly confirmed recently that microRNAs are involved in the mechanisms of leukocyte development, differentiation, and apoptosis, as well as in the pathogenesis of proliferative diseases of the hematopoietic system. Currently, research strategies allow determination of the deregulation of microRNA profiles in relation to other cytogenetic aberrations, as well as prognostic factors and primary end points. The problem of the possibility of their use as therapeutic targets is also increasingly discussed. In this article, we analyze literature data on abnormalities in microRNA expression in proliferative diseases of the hematopoietic system in the context of classic cytogenetic and molecular aberrations.
目前,癌症发生过程的研究主要集中在了解其遗传基础以及可能作为预测因素和治疗靶点的分子异常。最近已明确证实,微小RNA参与白细胞发育、分化和凋亡机制,以及造血系统增殖性疾病的发病机制。目前,研究策略能够确定与其他细胞遗传学异常、预后因素和主要终点相关的微小RNA谱失调情况。关于将其用作治疗靶点的可能性问题也日益受到讨论。在本文中,我们结合经典细胞遗传学和分子异常情况,分析了有关造血系统增殖性疾病中微小RNA表达异常的文献数据。